Investor FAQs · Email Alerts · Contact Us · Investor Relations. News Release Details. Facebook · Twitter · Email; Tumblr; LinkedIn · News & Events · Stock ...
AveXis Reports First Quarter 2018 Financial and Operating Results · Cash Position: As of March 31, 2017, AveXis had $586.8 million in cash and cash equivalents.
We have successfully completed engineering lots for both AVXS-201 and AVXS-301. ... investor relations, disclosure and similar requirements applicable to public ...
People also ask
How much did Novartis pay for AveXis?
When did AveXis become Novartis gene therapies?
Is Zolgensma FDA approved?
... investor relations, disclosure and similar requirements applicable to public reporting companies. Interest Income, net. Interest income primarily consists of ...
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports ( ...
Analysts and investors can participate in the conference call by dialing (844) 889-6863 for domestic callers and (661) 378-9762 for international callers, using ...
Missing: relations | Show results with:relations
Retired Vice President, Investor Relations and Corporate Communications, AveXis, Inc. · View mutual connections with Jim · Welcome back · Activity · Experience.
Apr 9, 2018 · Investor Relations. Page 2. Disclaimer. 2. This presentation ... 3 Agreement to Acquire AveXis | April 9, 2018 | Novartis Investor Presentation.
Nov 10, 2017 · Analysts and investors can participate in the conference call by dialing (844) 889-6863 for domestic callers and (661) 378-9762 for ...
Missing: relations | Show results with:relations
May 5, 2019 · fSpeer259@avexis.com. Novartis Investor Relations. Central investor relations line: +41 61 324 7944. E-mail: investor.relations@novartis.com.